Hua Liao, Shiyu Yang, Nan Zhang, Juan Du, Hui Yuan, Lili Pan
{"title":"Elevated serum uric acid is a predictor of pulmonary artery involvement and subsequent prognosis in patients with Takayasu's arteritis.","authors":"Hua Liao, Shiyu Yang, Nan Zhang, Juan Du, Hui Yuan, Lili Pan","doi":"10.55563/clinexprheumatol/cv6z35","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to investigate the predictive value of uric acid (UA) in prognosis of pulmonary artery involvement (PAI) in patients with Takayasu's arteritis (TAK).</p><p><strong>Methods: </strong>A total of 166 TAK patients were enrolled in the study, including 76 with PAI and 90 without. Outcomes of 144 TAK patients were followed up and recorded. The possible associations between serum UA levels and incidence of PAI in TAK and PAI-related prognosis of TAK patients were examined using different statistical models.</p><p><strong>Results: </strong>The serum UA levels were significantly higher in TAK patient with PAI than TAK patients without PAI. Multivariate logistic regression analysis indicated that serum UA level ≥284.5 umol/L was associated with an increasing incidence of PAI in TAK (OR: 2.108, 95% CI: 1.063 to 4.180; p=0.033). Kaplan-Meier survival analysis showed that TAK patients with serum UA level ≥328.1 umol/L had a significantly higher cumulative incidence of PAI-related adverse events compared to TAK patients with serum UA level <328.1 umol/L (p=0.008). Multivariate Cox proportional hazard regression analysis revealed that serum UA level ≥328.1 umol/L (HR: 2.595, 95% CI: 1.198 to 5.622; p=0.016) was a PAI-related prognostic risk factor for TAK.</p><p><strong>Conclusions: </strong>Elevation of serum UA level was associated with an increasing risk of PAI and PAI-related adverse event in patients with TAK, indicating its potential as a predictor for identification of PAI onset and worsening in TAK patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"602-610"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/cv6z35","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The aim of this study was to investigate the predictive value of uric acid (UA) in prognosis of pulmonary artery involvement (PAI) in patients with Takayasu's arteritis (TAK).
Methods: A total of 166 TAK patients were enrolled in the study, including 76 with PAI and 90 without. Outcomes of 144 TAK patients were followed up and recorded. The possible associations between serum UA levels and incidence of PAI in TAK and PAI-related prognosis of TAK patients were examined using different statistical models.
Results: The serum UA levels were significantly higher in TAK patient with PAI than TAK patients without PAI. Multivariate logistic regression analysis indicated that serum UA level ≥284.5 umol/L was associated with an increasing incidence of PAI in TAK (OR: 2.108, 95% CI: 1.063 to 4.180; p=0.033). Kaplan-Meier survival analysis showed that TAK patients with serum UA level ≥328.1 umol/L had a significantly higher cumulative incidence of PAI-related adverse events compared to TAK patients with serum UA level <328.1 umol/L (p=0.008). Multivariate Cox proportional hazard regression analysis revealed that serum UA level ≥328.1 umol/L (HR: 2.595, 95% CI: 1.198 to 5.622; p=0.016) was a PAI-related prognostic risk factor for TAK.
Conclusions: Elevation of serum UA level was associated with an increasing risk of PAI and PAI-related adverse event in patients with TAK, indicating its potential as a predictor for identification of PAI onset and worsening in TAK patients.
研究目的本研究旨在探讨尿酸(UA)对高安氏动脉炎(TAK)患者肺动脉受累(PAI)预后的预测价值:研究共纳入166名TAK患者,其中76人患有肺动脉受累,90人未患有肺动脉受累。对144名TAK患者的结果进行了随访和记录。采用不同的统计模型研究了血清 UA 水平与 TAK PAI 发病率之间可能存在的关联,以及 TAK 患者与 PAI 相关的预后:结果:有PAI的TAK患者血清UA水平明显高于无PAI的TAK患者。多变量逻辑回归分析表明,血清UA水平≥284.5 umol/L与TAK患者PAI发生率增加有关(OR:2.108,95% CI:1.063~4.180;P=0.033)。Kaplan-Meier生存分析显示,与血清UA水平≥328.1 umol/L的TAK患者相比,血清UA水平≥328.1 umol/L的TAK患者发生PAI相关不良事件的累积发生率明显更高:血清 UA 水平升高与 TAK 患者发生 PAI 和 PAI 相关不良事件的风险增加有关,表明其有可能成为识别 TAK 患者 PAI 发病和恶化的预测因子。
期刊介绍:
Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.